Academic Research Enhancement Award (AREA R15) Grants

Academic Research Enhancement Award (AREA) Grants – (R15) support small research projects in the biomedical and behavioral sciences which have not been major recipients of NIH research funds. The grants are intended to provide a small amount of funding so students can get hands-on research experience.

Because the R15 mechanism is rather unconventional with small budgets, crafting a clever and highly focused proposal that is seen as achievable becomes the key to an R15 success. With only 26% of new applications getting approved, you have to do everything possible to stand out from the crowd and convince the NIH you are worthy.

This uniquely focused webinar will cover the specifics of R15 grants to help you decide whether or not you qualify, what to include and exclude in your application, the importance of contacting the appropriate IC personnel, and much more. Plus, follow these insider tips to ensure you include the specific criteria reviewers are looking for.
5 Key Take-Aways:

- Creating a highly focused application that will win R15s
- How to interact with program official for guidance while preparing the application
- How to write your budget
- Managing time-lines and deadlines effectively
- Responding to initial critiques and summary statement
Dr. Sridhar Mani (Shri), is a Professor of Medicine and Genetics at the Albert Einstein College of Medicine, Bronx, NY. He was the Founding Director of the Phase I Experimental Therapeutics Program at the Montefiore/Einstein Cancer Center. He received his MD degree (1990) from the Mount Sinai School of Medicine, New York, NY followed by further postdoctoral training in Internal Medicine (Board Certified)(1990-1992) and Hematology/Oncology (Board Certified, Onc 1992-1995) at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT. Subsequently, he was the program leader for gastrointestinal oncology at the University of Chicago, Chicago, IL. During his tenure as a medical student, he did summer work at Rockefeller and then as a postdoctoral fellow at Yale, he studied under Dr. Eric Fearon on the role of DCC in colon cancer. In 1998, he returned to NY (Albert Einstein College of Medicine) to develop a Phase I Program in Oncology and a laboratory effort on drug metabolism. He is the recipient of the Clinical Investigator Award from the Damon Runyon Foundation (New York) and presently is an NIH funded Investigator on the role of orphan nuclear receptors in metabolism. He is a permanent member of the Developmental Therapeutics Study Section of NCI and serves as an editorial board member for Cancer Research, Clinical Cancer Research and Molecular Cancer Therapeutics (AACR). He has more than 100 peer-reviewed papers in journals like Science, Cancer Research, Clinical Cancer Research, Molecular Pharmacology, Molecular Endocrinology, Molecular Cancer Therapeutics, and Journal of Clinical Oncology.